New treatment for Waldenström’s macroglobulinemia now available

A new treatment for Waldenström’s macroglobulinemia (WM) has been approved by the Therapeutic Goods Administration for adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy, and also for adult patients with mantle cell lymphoma.

BRUKINSA (zanubrutinib) was developed by BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

WMozzies was proud to be invited by the Pharmaceutical Benefits Advisory Committee (PBAC) to take part in a pilot program as consumer advocates in the BRUKINSA PBAC decision process.

In a first for the PBAC, BeiGene expects to enter a facilitated resolution pathway in order to seek a listing date for WM.

Access to Brukinsa

Whilst the PBAC is considering the PBS listing of Brukinsa, some patients may be able to access the product via their specialist. Please discuss access options with your doctor.


BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesised, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimising bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease relevant tissues.

For more information, see Products | BeiGene

COVID-19 questions in WhiMSICAL Registry

WM Patients anywhere in the world can participate, whether or not they have been tested, or had the infection.. They can complete the Registry questionnaire, which now includes COVID-19 specific questions, To take part, you can login or register and consent at, and then answer the questions. Answers can be continually updated, so if you are tested later, you can enter the results of your COVID-19 test as soon as it is available and afterwards, return to update how COVID-19 impacted you. If you become unwell, you can have your close ones update your answers for you (with your login details). That way you will be helping researchers get the full picture of how severely COVID-19 impacts WM patients.

The COVID-19 question can be accessed at question 19 of the Questionnaire at . For those new to WhiMSICAL, please provide registration details (questions 1 and 2), Consent and enter “Waldenström’s Macroglobulinemia” as your diagnosis (question 3). All participants should complete the COVID-19 questions (question 19) and enter or update details of your treatment (question 9) and quality of life (questions 20 and 21). We also encourage you to enter or update details in other questions as we seek to provide big-data to describe the WM patient experience with WhiMSICAL. A valuable project you can complete in stages during your social distancing!

For further information on WhiMSICAL, click here (link),     or contact       or phone Andrew Warden Mob.0408 303 718

Virtual Lecture on WM

Virtual Lecture on WM

The lecture on Waldenström’s Macroglobulinemia, featuring Dr. Ansell, Professor of Medicine in the Division of Hematology at the Mayo Clinic, Rochester, MN, is now available.   WM topics covered include:

·          Who needs treatment at presentation

·          Treatment options for newly diagnosed and relapsed patients

To see Dr. Ansell’s lecture, available at The Leukemia & Lymphoma Society (LLS) website, click here.

LLS Virtual Lecture Programs offer a convenient opportunity to learn about the latest disease-specific information from medical experts. Dr. Ansell’s pre-recorded presentation on WM will be available to view for approximately 12 – 18 months. You can view the synchronized audio and slides, download the transcript, or request a hard copy of the transcript by contacting the Leukemia & Lymphoma Society at (link sends e-mail).

WhiMSICAL “Frequently Asked Questions” enhanced WhiMSICAL “Frequently Asked Questions” enhanced

WhiMSICAL “Frequently Asked Questions” enhanced

Following feedback from WhiMSICAL members, the “Frequently Asked Questions” at  has been enhanced with additional explanatory detail.  Many screenshots have been included to assist in important areas such as getting started, consent, diagnosis, and pathology results.

Register for WhiMSICAL at:

For further information or assistance send email to:

Please remember the cut-off for joining WhiMSICAL and updating details is in a week.

Act now so that your WM details are part of the WhiMSICAL submission to the ASH meeting in December.

New Website for WMozzies

New Website is being developed for WMozzies.

The release date is still being worked out.

If you would like to hear when it is launched join our mailing list via the Contact Page.